The Ombudsman did not publish his provisional views in November 2023 or at any other time. The Ombudsman published his final views on 21st March 2024.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3926", "label" : {"_value" : "Biography information for Paul Maynard"} } , "answeringMemberConstituency" : {"_value" : "Blackpool North and Cleveleys"} , "answeringMemberPrinted" : {"_value" : "Paul Maynard"} , "dateOfAnswer" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-15T14:13:12.267Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "29"} , "answeringDeptShortName" : {"_value" : "Work and Pensions"} , "answeringDeptSortName" : {"_value" : "Work and Pensions"} , "date" : {"_value" : "2024-03-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "State Retirement Pensions: Women"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Work and Pensions, if he will publish his Department's (a) communications and (b) minutes relating to the Parliamentary and Health Service Ombudsman's provisional views on injustice and remedy experienced due to maladministration in communication about the 1995 Pensions Act which were set out in the report published in November 2023.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4640", "label" : {"_value" : "Biography information for David Linden"} } , "tablingMemberConstituency" : {"_value" : "Glasgow East"} , "tablingMemberPrinted" : [{"_value" : "David Linden"} ], "uin" : "20382"} , {"_about" : "http://data.parliament.uk/resources/1698078", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1698078/answer", "answerText" : {"_value" : "
The Department does not collect the information requested.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-15T10:45:23.297Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "29"} , "answeringDeptShortName" : {"_value" : "Work and Pensions"} , "answeringDeptSortName" : {"_value" : "Work and Pensions"} , "date" : {"_value" : "2024-03-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Universal Credit: Payments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Work and Pensions, what the most common reasons cited on split payment applications are; and what assessment his Department has made of the (a) suitability and (b) effectiveness of the application process in the light of those reasons.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4640", "label" : {"_value" : "Biography information for David Linden"} } , "tablingMemberConstituency" : {"_value" : "Glasgow East"} , "tablingMemberPrinted" : [{"_value" : "David Linden"} ], "uin" : "20100"} , {"_about" : "http://data.parliament.uk/resources/1673236", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1673236/answer", "answerText" : {"_value" : "
We are aware of disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD), primarily driven by issues which have resulted in capacity constraints at key manufacturing sites.<\/p>
The National Patient Safety Alert to the National Health Service advises healthcare professionals on the management of patients during this time. We have well-established processes for managing and mitigating medicine supply issues, which involve working with the pharmaceutical industry, the Medicines and Healthcare products Regulatory Agency, NHS England, the devolved governments and others operating in the supply chain to help ensure patients have access to the treatments they need.<\/p>
The Department has been working closely with the respective manufacturers and some issues have now been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, including Xaggitin XL 18 and 36 milligrams, which are expected to resolve in early 2024.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"} } , "answeringMemberConstituency" : {"_value" : "Pendle"} , "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"} , "dateOfAnswer" : {"_value" : "2023-11-30", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-11-30T13:27:40.66Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2023-11-27", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Methylphenidate: Shortages"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the National Patient Safety Alert entitled Shortage of methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-release tablets, issued on 27 September 2023, alert reference NatPSA/2023/011/DHSC, what progress she has made on tackling supply disruptions affecting Xaggitin XL 18 and 36 mg prolonged-release tablets.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4640", "label" : {"_value" : "Biography information for David Linden"} } , "tablingMemberConstituency" : {"_value" : "Glasgow East"} , "tablingMemberPrinted" : [{"_value" : "David Linden"} ], "uin" : "3916"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }